Between 2016 and 2020, the company NanoThea carried out a project co-financed by the European Funds titled “Development of Biopolymer Nanoparticles for Precise Diagnosis and Targeted Therapy of Prostate Cancer Using Radioisotopes.”

The aim of the project was to develop a safe and effective radiopharmaceutical composed of radioisotope-labeled nanoparticles for theranostics (combined diagnostics and therapy) of prostate cancer.

Total project value: PLN 1,458,085.13
EU funding amount: PLN 1,157,507.89